26891877 |
Leukemogenic potency of the novel FLT3-N676K mutant
Huang, K,
Yang, M,
Pan, Z,
Heidel, FH,
Scherr, M,
Eder, M,
Fischer, T,
Büsche, G,
Welte, K,
von Neuhoff, N,
Ganser, A,
Li, Z
|
Ann. Hematol. |
2016 |
18483393 |
Identification of a novel type of ITD mutations located in nonjuxtamembrane domains of the FLT3 tyrosine kinase receptor
Breitenbuecher, F,
Schnittger, S,
Grundler, R,
Markova, B,
Carius, B,
Brecht, A,
Duyster, J,
Haferlach, T,
Huber, C,
Fischer, T
|
Blood |
2009 |
16410449 |
Point mutations in the juxtamembrane domain of FLT3 define a new class of activating mutations in AML
Reindl, C,
Bagrintseva, K,
Vempati, S,
Schnittger, S,
Ellwart, JW,
Wenig, K,
Hopfner, KP,
Hiddemann, W,
Spiekermann, K
|
Blood |
2006 |
15178581 |
Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AML
Jiang, J,
Paez, JG,
Lee, JC,
Bo, R,
Stone, RM,
Deangelo, DJ,
Galinsky, I,
Wolpin, BM,
Jonasova, A,
Herman, P,
Fox, EA,
Boggon, TJ,
Eck, MJ,
Weisberg, E,
Griffin, JD,
Gilliland, DG,
Meyerson, M,
Sellers, WR
|
Blood |
2004 |
12969963 |
FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells
Zheng, R,
Levis, M,
Piloto, O,
Brown, P,
Baldwin, BR,
Gorin, NC,
Beran, M,
Zhu, Z,
Ludwig, D,
Hicklin, D,
Witte, L,
Li, Y,
Small, D
|
Blood |
2004 |
30332834 |
Targeting Oncogenic Signaling in Mutant FLT3 Acute Myeloid Leukemia: The Path to Least Resistance
Staudt, D,
Murray, HC,
McLachlan, T,
Alvaro, F,
Enjeti, AK,
Verrills, NM,
Dun, MD
|
Int J Mol Sci |
2018 |
14984498 |
Novel FLT3 point mutations within exon 14 found in patients with acute myeloid leukaemia
Stirewalt, DL,
Meshinchi, S,
Kussick, SJ,
Sheets, KM,
Pogosova-Agadjanyan, E,
Willman, CL,
Radich, JP
|
Br. J. Haematol. |
2004 |
11290608 |
Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies
Yamamoto, Y,
Kiyoi, H,
Nakano, Y,
Suzuki, R,
Kodera, Y,
Miyawaki, S,
Asou, N,
Kuriyama, K,
Yagasaki, F,
Shimazaki, C,
Akiyama, H,
Saito, K,
Nishimura, M,
Motoji, T,
Shinagawa, K,
Takeshita, A,
Saito, H,
Ueda, R,
Ohno, R,
Naoe, T
|
Blood |
2001 |
16266983 |
Constitutive activation of Akt by Flt3 internal tandem duplications is necessary for increased survival, proliferation, and myeloid transformation
Brandts, CH,
Sargin, B,
Rode, M,
Biermann, C,
Lindtner, B,
Schwäble, J,
Buerger, H,
Müller-Tidow, C,
Choudhary, C,
McMahon, M,
Berdel, WE,
Serve, H
|
Cancer Res. |
2005 |
15256420 |
Variable sensitivity of FLT3 activation loop mutations to the small molecule tyrosine kinase inhibitor MLN518
Clark, JJ,
Cools, J,
Curley, DP,
Yu, JC,
Lokker, NA,
Giese, NA,
Gilliland, DG
|
Blood |
2004 |
18068628 |
Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles
Fröhling, S,
Scholl, C,
Levine, RL,
Loriaux, M,
Boggon, TJ,
Bernard, OA,
Berger, R,
Döhner, H,
Döhner, K,
Ebert, BL,
Teckie, S,
Golub, TR,
Jiang, J,
Schittenhelm, MM,
Lee, BH,
Griffin, JD,
Stone, RM,
Heinrich, MC,
Deininger, MW,
Druker, BJ,
Gilliland, DG
|
Cancer Cell |
2007 |
30651634 |
Targeting FLT3 mutations in AML: review of current knowledge and evidence
Daver, N,
Schlenk, RF,
Russell, NH,
Levis, MJ
|
Leukemia |
2019 |
16990784 |
FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248)
Schittenhelm, MM,
Yee, KW,
Tyner, JW,
McGreevey, L,
Haley, AD,
Town, A,
Griffith, DJ,
Bainbridge, T,
Braziel, RM,
O'Farrell, AM,
Cherrington, JM,
Heinrich, MC
|
Leukemia |
2006 |
9737679 |
Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product
Kiyoi, H,
Towatari, M,
Yokota, S,
Hamaguchi, M,
Ohno, R,
Saito, H,
Naoe, T
|
Leukemia |
1998 |
29964125 |
Structural and clinical consequences of activation loop mutations in class III receptor tyrosine kinases
Klug, LR,
Kent, JD,
Heinrich, MC
|
Pharmacol. Ther. |
2018 |